On the stock market since 2015, it operates in the world of health and science. It has 33 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $531K against $0 in annual sales.
This stock swings about 2.4 times as much as the market average. Big rallies — and big drops — can both happen fast.
Over the last 12 months, executives reported 16 sells against just 0 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, BVXV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BVXV is a high-risk stock — not yet profitable, and its future rides on its product catching on.